State of the art--treatment of peripheral occlusive arterial disease (POAD) with drugs vs. vascular reconstruction or amputation.
Peripheral occlusive arterial disease (POAD) is a disease with a progressive course in about half of the patients affected. The Fontaine stage II and III have been treated not always successfully in the last decades with physical exercise, vasoactive substances (pentoxifyllin, naftidrofuryl, buflomedil) and with alprostadil. Recently methods of vascular surgery such as PTA, stent implantation and bypass operations are introduced in the treatment of Fontaine POAD stages III and IV, but these procedures are not recommended in patients younger than 50 years in order to delay amputation of a limb. The vasoactive substances are seen in a new light, because they improve processes of the microcirculation such as decreasing plasma viscosity, the raised plasma fibrinogen level and increasing the deformability of red blood cells and inhibiting platelet aggregation. According to a number of studies pentoxifylline and naftidrofuryl may delay the progression of arteriosclerosis. Therefore, a new concept of the treatment of POAD must be evaluated (1) resulting in a combination of vascular surgery and intermittent drug therapy with vasoactive agents, (2) leading to a decrease in the risk of amputation frequency and (3) reducing the treatment costs in spite of a higher frequency of the disease and a longer average life expectancy.
Haustein
K O
KO
Klinikum der Friedrich-Schiller-Universität Jena, Germany.
D000671:Amputation, Surgical; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D006801:Humans; D008019:Life Style; D016491:Peripheral Vascular Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D012307:Risk Factors
D002317:Cardiovascular Agents